VENT-03 is the first oral small-molecule cyclic GMP-AMP synthase (cGAS) inhibitor to successfully complete a first-in-human Phase 1 study and was discovered using Ventus’ proprietary ReSOLVE ...

Review the current PT Citra Nusantara Gemilang Tbk (CGAS:XIDX) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if CGAS is the best investment for you.

In vivo, in rats with ventricular fibrillation (VF)-induced CA, a selective cGAS inhibitor (RU.521) was used to specifically inhibit cGAS activity, thereby blocking its downstream signaling pathway.

Reviews EcoFlow Power Hat review: A sun hat with solar panels Take advantage of the sun when you're out with your devices. By Halyna Kubiv Staff Writer, Macwelt MAY 10, 2025 1:10 am PDT ...

CROFTON, Md. — The Preakness Stakes brings out the best in fashion, and there's so much new for 2025. Marjae Hats explained the history of hat-wearing at the Preakness and revealed this year's ...

From traditional hats to fascinators and headdresses, the best looks at the 151st running of America’s most fashionable sporting event. Rain at Churchill Downs altered the plans for many at this ...

WALTHAM, Mass. & MONTREAL — Ventus Therapeutics, a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and ...

As with all great discoveries, the discovery of cGAS was built on a foundation of previous work. Efforts that began in the late 1990s established that a transmembrane receptor for DNA called toll ...

And this deficiency, Chen and colleagues have found, can end up triggering the cGAS alarm system. This hints that cGAS could be key to reining in these harmful immune responses.